Valuation: Charles River Laboratories International, Inc.

Market Cap 1.13TCr 984.32Cr 907.71Cr 839.86Cr 1.59TCr 1,07400Cr 1.62TCr 11TCr 4.26TCr 53TCr 4.22TCr 4.13TCr 1,82700Cr P/E 2026 *
38.1x
P/E 2027 * 25.5x
Enterprise Value 1.31TCr 1.14TCr 1.05TCr 975.22Cr 1.85TCr 1,24700Cr 1.88TCr 13TCr 4.95TCr 61TCr 4.9TCr 4.8TCr 2,12100Cr EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.22x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-10.60% - - 1.08TCr
+1.68%+3.19%+3.55%+10.97% 4.94TCr
+0.72%+1.00%+396.18%+624.25% 4.03TCr
+2.54%+0.93%+28.98%-3.62% 3.4TCr
+0.31%+1.74%+18.44%+59.76% 3.36TCr
-2.09%-1.98%+3.21%+33.56% 2.68TCr
-0.63%+0.34% - - 1.72TCr
+0.66%-3.96%+66.85%+127.36% 1.52TCr
-23.90%-21.43%+50.06%+53.83% 1.4TCr
+2.59%-0.49%+15.24%+21.25% 1.34TCr
Average -2.05%-2.30%+72.81%+115.92% 2.71TCr
Weighted average by Cap. -0.68%-0.86%+87.20%+138.87%

Financials

2026 *2027 *
Net sales 385.1Cr 336.88Cr 310.66Cr 287.44Cr 545.58Cr 37TCr 554.7Cr 3.72TCr 1.46TCr 18TCr 1.45TCr 1.41TCr 63TCr 392.2Cr 343.09Cr 316.39Cr 292.74Cr 555.63Cr 37TCr 564.92Cr 3.79TCr 1.49TCr 18TCr 1.47TCr 1.44TCr 64TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.72TCr 41Cr 275.46Cr 107.98Cr 1.34TCr 107.04Cr 104.72Cr 4.63TCr 42Cr 37Cr 34Cr 31Cr 59Cr 3.98TCr 60Cr 403.16Cr 158.04Cr 1.96TCr 156.66Cr 153.28Cr 6.78TCr
Net Debt 181.35Cr 158.65Cr 146.3Cr 135.36Cr 256.93Cr 17TCr 261.22Cr 1.75TCr 686.81Cr 8.5TCr 680.82Cr 666.09Cr 29TCr 138.72Cr 121.36Cr 111.91Cr 103.54Cr 196.53Cr 13TCr 199.82Cr 1.34TCr 525.36Cr 6.5TCr 520.78Cr 509.52Cr 23TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Trader
Investor
Global
Quality
ESG MSCI
AA